Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | DRD1 | P21728 | 3/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.60 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | CES1 | P23141 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4538268 | 1.00 | ABCB11 (0.60) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL29078167 | 0.88 | DRD1 (0.57) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL14207878 | 0.85 | DRD1 (0.47) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL12723123 | 0.82 | DRD1 (0.45) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL4564635 | 0.82 | ABCB11 (0.60) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL4564637 | 0.82 | ABCB11 (0.60) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL14407225 | 0.81 | ABCB11 (0.43) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL10952840 | 0.81 | DRD1 (0.64) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL12604040 | 0.81 | DRD1 (0.64) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL16706904 | 0.81 | DRD1 (0.64) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321785-B2 | Methods for the treatment or prophylaxis of thrombosis or embolism | IPCA LABORATORIES LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| US-9321785-B2 | Methods for the treatment or prophylaxis of thrombosis or embolism | IPCA LABORATORIES LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| US-20150307513-A1 | COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA LAB LTD (IN) | 2015-10-29 | — | — | US | disclosed |
| US-20140018331-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA LABORATORIES LIMITED (IN) | 2014-01-16 | — | — | US | disclosed |
| US-20140018331-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA LABORATORIES LIMITED (IN) | 2014-01-16 | — | — | US | disclosed |
| EP-2540729-A1 | (7aS, 2'S)-2-Oxoclopidogrel as anti-thrombotic compound | IPCA Laboratories Limited (IN) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012025942-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA LABORATORIES LIMITED (IN) | 2012-03-01 | — | — | WO | disclosed |
| WO-2008062421-A1 | A PROCESS FOR PREPARING (S)-(+)-CLOPIDOGREL BASE AND ITS SALTS | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018331-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | F2, PLAT, SELP | ABCB11 329/4885CYP2C19 48/4885DRD1 3413/4885 |
| US-20150307513-A1 | COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | PLA2G7, F2, PLTP | ABCB11 465/4885CYP2C19 68/4885DRD1 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.